Management of Hypersensitivity Reactions to Taxanes - 30/09/17
Résumé |
Taxanes are an important class of antineoplastic agents used in the treatment of a wide variety of cancers. However, paclitaxel and docetaxel, which are the most commonly used taxanes, elicit immediate hypersensitivity reactions (HSRs) in 5% to 10% of patients. Almost all patients that experience these reactions can be safely re-exposed to taxanes either through desensitization or challenge. This article describes the clinical presentation, diagnosis, and management of HSRs to taxanes and discusses the different options for their safe readministration.
Le texte complet de cet article est disponible en PDF.Keywords : Taxane, Paclitaxel, Docetaxel, Allergy, Hypersensitivity, Skin test, Desensitization and challenge
Plan
| Disclosures: No funding was received for this work. M. Picard has received consultancy fees from Algorithme Pharma, and has received lecture fees from Sanofi and Nestle. |
Vol 37 - N° 4
P. 679-693 - novembre 2017 Retour au numéro
Article précédent
- Platinum Chemotherapy Hypersensitivity : Prevalence and Management
- Iris M. Otani, Johnson Wong, Aleena Banerji
- Monoclonal Antibodies Hypersensitivity : Prevalence and Management
- Rafael Bonamichi Santos, Violeta Régnier Galvão
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?